ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
주요 하이라이트 :
허리 신경근증은 요추 신경근에서 발생하는 자연 치유성 손상입니다. 격렬한 통증, 작열감, 찌르는 통증이 다리에 흩어지거나 다리의 감각 저하, 저림과 따끔거림, 심한 경우에는 근력 저하를 동반 할 수 있습니다.
DelveInsight의 추정에 따르면, 허리 신경 근증이라고도 불리는 요천추 신경근 통증은 매우 흔한 질병입니다. 평균적으로 성인의 3-5%가 평생 증상을 경험하고 L5 신경근증이 요부 신경근증 중 가장 빈도가 높은 단일 질환입니다.
2023년 현재 미국 7개국에서 허리 신경근증의 총 사례의 약 50%를 차지하고 있습니다.
요천추 신경근 통증의 파이프라인은 그다지 탄탄하지는 않지만, Scilex Holdings가 개발 중인 3상 임상시험 단계에 있는 SEMDEXA가 유망한 약물 후보입니다.
대상 지역 :
미국
EU 4개국(독일, 프랑스, 이탈리아, 스페인) 및 영국
일본
요천추 신경근 통증 보고서 : 통찰력
환자 인구
치료 접근
파이프라인 분석
시장 규모·동향
기존 및 미래 시장 기회
요천추 신경근 통증 보고서 : 주요 강점
11년간의 예측
주요 7개국 커버리지
역학 세분화
국가별 치료 가이드라인의 수재
신규 치료에 관한 KOL의 견해
주요 교차 경쟁
컨조인트 분석
치료제의 도입·시장 예측의 주된 전제조건
요천추 신경근 통증 보고서 : 평가
현재의 치료법
미충족 요구
파이프라인 제품프로파일
시장의 매력
정성 분석(SWOT· 컨조인트 분석)
본 보고서는 요천추 신경근 통증의 역학, 시장, 임상개발에 대한 상세한 분석을 제공하고 미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본에서 요천추 신경근 통증의 역학 및 시장 규모 추이와 예측 데이터 및 시장 동향의 상세한 분석을 제공합니다.
또한 실제 처방 패턴 분석, 신규약제 평가, 시장 점유율, 치료제별 채택·보급 패턴, 현재 요천추 신경근 통증 치료의 실천/알고리즘과 미충족 요구도 망라하여 최적 시장 기회를 파악하고 요천추 신경근 통증 시장이 가지는 잠재가치를 평가했습니다.
목차
제1장 중요한 통찰
제2장 보고서 개요
제3장 주요 요약
제4장 주요 사건
제5장 역학·시장 예측 수법
제6장 요천추 신경근 통증 : 시장 개요
시장 점유율 실적(%)
시장 점유율 예측(%)
제7장 질환 배경과 개요 : 요천추 신경근 통증
신경근통의 분류
요천추 신경근 통증의 임상적 특징
증상
합병증과 위험인자
진단
감별 진단
제8장 요천추 신경근 통증의 진단 알고리즘
제9장 역학과 환자 인구 : 주요 7개국
주요 조사 결과
가정과 근거
주요 7개국의 진단 유병 환자수
미국
EU 4개국 및 영국
일본
진단 유병 환자 수
유병 환자수 : 성별
미국의 유병 환자수 : 연령별
미국의 치료 유병 환자수
제10장 환자 여정
제11장 시판 치료제
NUCALA: GSK
제품 설명
규제 마일스톤
기타 발달 활동
임상 개발 활동
안전성과 유효성
제12장 신규 치료제
주요 교차 경쟁
Depemokimab: GlaxoSmithKline
제품 설명
기타 발달 활동
임상 개발 활동
안전성과 유효성
애널리스트의 견해
제13장 요천추 신경근 통증 : 시장 규모
주요 조사 결과
시장 전망
컨조인트 분석
주요 시장 예측의 전제조건
주요 7개국의 총 시장 규모
미국
EU 4개국 및 영국
일본
총 시장 규모
시장 규모 : 치료제별
제14장 미충족 요구
제15장 SWOT 분석
제16장 KOL의 견해
제17장 시장 접근과 상환
미국
EU 4개국 및 영국
일본
제18장 부록
제19장 DelveInsight의 서비스 내용
제20장 면책사항
제21장 DelveInsight 정보
SHW
영문 목차
영문목차
Key Highlights:
Lumbar radiculopathy is a self-limited injury to the nerve roots of the lumbar spine. It can present as excruciating, burning, or stinging pain, radiating down the leg, decreased sensation of the legs, numbness and tingling, and in more severe cases, muscle weakness.
According to DelveInsight's estimates, lumbosacral radicular pain also known as lumbosacral radiculopathy, is very common. On average, 3 to 5% of adults will experience symptoms in their lifetime and L5 radiculopathy is the single most common Lumbar Radiculopathy.
In 2023, the United States accounted for approximately 50% of the total cases of lumbosacral radiculopathy in the 7MM.
Lumbosacral radicular pain pipeline is also not so robust but possesses a potential drug candidate i.e. SEMDEXA, which is currently in Phase III clinical trials developed by Scilex Holdings.
DelveInsight's "Lumbosacral Radicular Pain- Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Lumbosacral Radicular Pain, historical and forecasted epidemiology as well as the Lumbosacral Radicular Pain market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Lumbosacral Radicular Pain market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Lumbosacral Radicular Pain market size from 2020 to 2034. The report also covers current Lumbosacral Radicular Pain treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.
Geography Covered:
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Lumbosacral Radicular Pain Understanding and Treatment Algorithm
Lumbosacral Radicular Pain Overview, Country-Specific Treatment Guidelines and Diagnosis
Acute lumbosacral radiculopathy is a diffuse disease process that affects more than one underlying nerve root, causing pain, loss of sensation, and motor function depending on the severity of nerve compression. Lumbosacral radiculopathy is very common. Most cases of lumbosacral radiculopathy are self-limited. The most common symptom in radiculopathy is paresthesia.
The most common causes of lumbar radiculopathy are either a herniated disc with resultant nerve root compression or spondylosis.
To diagnose a herniated disc as a source of a patient's pain, it is important to review the complete history and physical and making sure that the symptoms match the imaging results. Patients with lumbar radicular pain often respond to conservative management.
The Lumbosacral Radicular Pain report provides an overview of Lumbosacral Radicular Pain pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient's journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.
Lumbosacral Radicular Pain Treatment
Treatment varies depending on the etiology and severity of symptoms. Conservative management of symptoms is generally considered the first-line treatment. Medications are used to manage pain symptoms, including nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, anti-epileptic medications that can be used to treat nerve-related pain (e.g., gabapentin), and in severe cases, low-dose opiates. Systemic steroids are an option for lumbosacral radiculopathy, which can result in modest benefits.
Non-pharmacological interventions are often utilized as well. Physical therapy, acupuncture, chiropractic manipulation, and traction are all commonly used to treat lumbosacral radiculopathy.
Lumbosacral Radicular Pain Epidemiology
The Lumbosacral Radicular Pain epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Lumbosacral Radicular Pain epidemiology is segmented with detailed insights into Total Diagnosed Prevalent Cases, Severity-based Diagnosed Prevalent Cases of Lumbosacral Radicular Pain, and Prevalent cases of Lumbosacral Radicular Pain by species for the years [2020-2034].
Lumbosacral radiculopathy affects approximately 3% to 5% of the population. It is equally distributed between men and women.
The primary risk factor for lumbosacral radiculopathy is age, as it often occurs due to degenerative changes in the spinal column.
Patients with lumbosacral radiculopathy commonly experience pain, numbness, and weakness in the back, groin, or leg. The most frequent causes are compressive intervertebral disc herniation and degenerative spondylosis.
Lumbosacral Radicular Pain Drug Chapters
The drug chapter segment of the Lumbosacral Radicular Pain report encloses a detailed analysis of Lumbosacral Radicular Pain late-stage (Phase III) pipeline drugs. It also deep dives into the Lumbosacral Radicular Pain pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.
Emerging Drugs
SEMDEXA: Scilex Holding
SEMDEXA is a novel injectable corticosteroid gel formulation product in development for the treatment of lumbosacral radicular pain, which contains no preservatives, surfactants, solvents, or particulates. The CLEAR Trial (Corticosteroid Lumbosacral Epidural Analgesia for Radiculopathy) was designed to investigate safety and analgesic effects of a single and repeat transforaminal injections of SEMDEXA compared to placebo (saline injection). The trial enrolled 401 low back pain subjects with unilateral intervertebral lumbar disc herniation, resulting in radicular pain symptoms of moderate to severe leg pain. It is the largest known randomized well-controlled trial in sciatica using epidural steroid injections.
In June 2024, Scilex Holding announced a publication in PAIN journal regarding Phase III of pivotal registration trial of SEMDEXA in lumbosacral radicular pain.
Lumbosacral Radicular Pain Market Outlook
Key player, Scilex Holdings is evaluating its lead candidate SEMDEXA in late stage of clinical development, respectively. They aim to investigate their products for the treatment of lumbosacral radicular pain.
The market size of lumbosacral radicular pain in the seven major markets is expected to increase substantially from 2024 with upcoming drugs.
Physicial therapy and surgery plays a major role in the treatment of lumbosacral radiculopathy, with conservative pain management approach being used only in certain cases, as most patients end up being treated for the underlying disease itself. Hence only in those patients specifically requiring pharmacological pain management, drugs like NSAIDs, anticonvulsants, and antidepressants are used.
Although established guidelines discourage the usage of opioids, reserving their usage only to patients with severe pain, they have still been observed to be used frequently in the clinical setting.
Lumbosacral Radicular Pain Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024-2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.
Lumbosacral Radicular Pain Activities
The report provides insights into different therapeutic candidate in Phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Lumbosacral Radicular Pain emerging therapies.
KOL Views
To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.
DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as Nationwide Children's Hospital, Columbus, OH, the United States, University Hospitals Dorset NHS Foundation Trust, North Shore University Health System, Evanston, Illinois, etc., were contacted. Their opinion helps understand and validate current and emerging treatment patterns of Lumbosacral Radicular Pain. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
Conjoint Analysis analyzes therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Scope of the Report:
The report covers a segment of key events, an executive summary, descriptive overview of lumbosacral radicular pain, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
A detailed review of the lumbosacral radicular pain market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM lumbosacral radicular pain market.
Inclusion of Country specific treatment guidelines
KOL's feedback on emerging therapies
Key Cross Competition
Conjoint analysis
Drugs Uptake and Key Market Forecast Assumptions
Lumbosacral Radicular Pain Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Qualitative Analysis (SWOT and Conjoint Analysis)
FAQs:
What is the growth rate of the 7MM Lumbosacral Radicular Pain treatment market?
What was the Lumbosacral Radicular Pain total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
Is there any unexplored patient setting that can open the window for growth in the future?
What are the pricing variations among different geographies for off-label therapies?
How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
What are the current and emerging options for the treatment of Lumbosacral Radicular Pain?
How many companies are developing therapies for the treatment of Lumbosacral Radicular Pain?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
Patient acceptability in terms of preferred treatment options as per real-world scenarios?
Reasons to buy:
The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Lumbosacral Radicular Pain Market.
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Lumbosacral Radicular Pain
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Lumbosacral Radicular Pain Market Overview at a Glance
6.1. Market Share (%) Distribution of Lumbosacral Radicular Pain in 2020
6.2. Market Share (%) Distribution of Lumbosacral Radicular Pain in 2034
7. Disease Background and Overview: Lumbosacral Radicular Pain
7.1. Introduction
7.2. Classification of Radicular pain
7.3. Clinical Characteristics of Lumbosacral Radicular Pain
7.4. Symptoms
7.5. Complications and risk factors
7.6. Diagnosis
7.7. Differential diagnosis
8. Diagnostic Algorithm for Lumbosacral Radicular Pain
9. Epidemiology and Patient Cases: 7MM
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Total Diagnosed Prevalent Cases of Lumbosacral Radicular Pain in the 7MM
9.4. United States
9.4.1. Total Diagnosed Prevalent Cases of Lumbosacral Radicular Pain in the United States
9.4.2. Gender- specific prevalent cases of Lumbosacral Radicular Pain in the United States
9.4.3. Age-specific Prevalent Cases of Lumbosacral Radicular Pain in the United States
9.4.4. Treated Prevalent Cases of Lumbosacral Radicular Pain in the United States
9.5. EU4 and the UK
9.5.1. Total Diagnosed Prevalent Cases of Lumbosacral Radicular Pain in EU4 and the UK
9.5.2. Gender- specific prevalent cases of Lumbosacral Radicular Pain in EU4 and the UK
9.5.3. Age-specific Prevalent Cases of Lumbosacral Radicular Pain in EU4 and the UK
9.5.4. Treated Prevalent Cases of Lumbosacral Radicular Pain in EU4 and the UK
9.6. Japan
9.6.1. Total Diagnosed Prevalent Cases of Lumbosacral Radicular Pain in Japan
9.6.2. Gender- specific prevalent cases of Lumbosacral Radicular Pain in Japan
9.6.3. Age-specific Prevalent Cases of Lumbosacral Radicular Pain in Japan
9.6.4. Treated Prevalent Cases of Lumbosacral Radicular Pain in Japan
10. Treatment
11. Patient Journey
12. Unmet Needs
13. Emerging Drugs
13.1. SEMDEXA: Scilex Holdings
13.1.1. Product Description
13.1.2. Other Development Activities
13.1.3. Clinical Development
13.1.4. Safety and Efficacy
List to be continued in full report
14. Lumbosacral Radicular Pain: 7 Major Market Analysis
14.1. Key Findings
14.2. Market Outlook
14.3. Key Market Forecast Assumptions
14.4. Conjoint Analysis
14.5. Market Size of Lumbosacral Radicular Pain in the 7MM
14.6. United States Market Size
14.6.1. Total Market Size of Lumbosacral Radicular Pain in the US
14.6.2. Market Size by Therapies of Lumbosacral Radicular Pain in the US
14.7. EU4 and the UK Market Size
14.7.1. Total Market size of Lumbosacral Radicular Pain in EU4 and the UK
14.7.2. Market Size by Therapies of Lumbosacral Radicular Pain in EU4 and the UK
14.8. Japan Market Size
14.8.1. Total Market Size of Lumbosacral Radicular Pain in Japan
